Hospital
Baptist Medical Center - Yazoo, INC
Baptist Medical Center - Yazoo, INC was paid $11.60M by Medicaid between Jan 2018 and Dec 2024, across 138 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoBAPTIST MEDICAL CENTER - YAZOO, INC
YAZOO CITY, MS 39194
YAZOO CITY, MS 39194
33aNPI1619918075assigned 06/09/2006
33bProvider typeCritical Access Hospital
28Total paid$11.60M
24GClaims315,387
24DCodes billed138
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#3 of 32
Median peer was paid$3.94M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,381 | $1.62M | |
| 2019 | 41,417 | $1.78M | |
| 2020 | 36,223 | $1.34M | |
| 2021 | 44,767 | $1.62M | |
| 2022 | 57,891 | $1.81M | |
| 2023 | 54,896 | $1.95M | |
| 2024incomplete | 37,812 | $1.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 12,464 | 10,369 | $2.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 16,934 | 14,104 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,888 | 4,922 | $1.24M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 5,916 | 4,642 | $484K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 5,936 | 5,095 | $446K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.4% | 10,794 | 8,070 | $398K |
| G0378 | Hospital observation service, per hour | 3.3% | 949 | 698 | $380K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.6% | 3,389 | 2,189 | $306K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 2,895 | 2,353 | $253K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 3,254 | 2,758 | $252K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 4,075 | 2,464 | $248K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,800 | 1,514 | $247K |
126 more codes
| 71045 | Radiologic examination, chest; single view | 2.1% | 6,535 | $238K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.9% | 6,515 | $224K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 15,602 | $191K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 4,578 | $189K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 4,456 | $187K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 924 | $182K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 8,218 | $155K |
| 80053 | Comprehensive metabolic panel | 1.2% | 18,210 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 22,988 | $118K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 4,568 | $117K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,648 | $90K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,434 | $85K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,223 | $74K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 529 | $67K |
| 83880 | <1% | 3,330 | $63K | |
| 73560 | <1% | 1,264 | $55K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,338 | $45K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,632 | $45K |
| 84484 | <1% | 6,024 | $41K | |
| 81001 | <1% | 15,650 | $37K | |
| 74018 | <1% | 751 | $34K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,023 | $33K |
| 81025 | <1% | 5,457 | $33K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 435 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,413 | $31K |
| 73630 | <1% | 669 | $29K | |
| 80061 | Lipid panel | <1% | 2,917 | $28K |
| 73030 | <1% | 656 | $25K | |
| 80305 | <1% | 2,413 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,836 | $18K |
| 36600 | <1% | 681 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,031 | $16K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 74 | $16K |
| 73130 | <1% | 310 | $16K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 564 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 563 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,392 | $15K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 175 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 827 | $14K |
| 83690 | <1% | 2,933 | $14K | |
| 87040 | <1% | 2,292 | $13K | |
| 82803 | <1% | 772 | $13K | |
| 83605 | <1% | 1,954 | $11K | |
| 87807 | <1% | 1,029 | $11K | |
| 83735 | <1% | 2,695 | $11K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 202 | $11K |
| 87186 | <1% | 1,945 | $10K | |
| 73610 | <1% | 205 | $10K | |
| 72100 | <1% | 191 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 129 | $10K |
| A9270 | Non-covered item or service | <1% | 3,571 | $9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 117 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 165 | $8K |
| 71250 | <1% | 99 | $7K | |
| 82150 | <1% | 1,352 | $7K | |
| 87081 | <1% | 1,593 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 378 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,954 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,627 | $6K |
| 82553 | <1% | 698 | $6K | |
| 74019 | <1% | 85 | $6K | |
| 85379 | <1% | 1,043 | $6K | |
| 85610 | <1% | 2,388 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 165 | $5K |
| 82550 | <1% | 923 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 72 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 20 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 98 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $4K |
| 70486 | <1% | 32 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 169 | $3K |
| 96376 | <1% | 1,064 | $3K | |
| 85730 | <1% | 822 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $3K |
| 73502 | <1% | 46 | $2K | |
| 87070 | <1% | 201 | $1K | |
| 86900 | <1% | 49 | $1K | |
| 72131 | <1% | 13 | $1K | |
| 86592 | <1% | 389 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,653 | $1K |
| 86677 | <1% | 91 | $827.95 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,496 | $791.73 |
| 87205 | <1% | 187 | $619.67 | |
| 73110 | <1% | 16 | $581.18 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,714 | $567.36 |
| 84703 | <1% | 64 | $447.84 | |
| 96367 | <1% | 14 | $437.85 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 245 | $391.83 |
| 74021 | <1% | 16 | $382.21 | |
| 86901 | <1% | 49 | $375.45 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 32 | $365.96 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,641 | $347.98 |
| 85027 | <1% | 147 | $309.07 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 41 | $238.85 |
| 86803 | <1% | 14 | $232.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 117 | $221.20 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 516 | $217.12 |
| 87088 | <1% | 36 | $203.29 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,563 | $172.04 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 479 | $165.24 |
| 87077 | <1% | 36 | $152.94 | |
| 86850 | <1% | 31 | $86.20 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 403 | $76.45 |
| 84550 | <1% | 32 | $70.97 | |
| 82009 | <1% | 13 | $44.77 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 61 | $32.68 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 17 | $30.13 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 62 | $20.33 |
| J2704 | Injection, propofol, 10 mg | <1% | 111 | $18.29 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 264 | $12.02 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 819 | $5.67 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 26 | $2.77 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 140 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 32 | $0.00 |
| 90715 | 0% | 62 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 17 | $0.00 |
| 94760 | 0% | 108 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 145 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 37 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 12 | $0.00 |
| 36416 | 0% | 71 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 15 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 18 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 17 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.